SLRN
ACELYRIN, INC. Common Stock
NASDAQ: SLRN · HEALTHCARE · BIOTECHNOLOGY
$2.27
+0.00% today
Updated 2026-04-30
Market cap
$229.17M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.69
Dividend yield
—
52W range
$2 – $3
Volume
4.1M
ACELYRIN, INC. Common Stock (SLRN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | — | — | $115000.00 | — |
| Gross profit | — | — | $-115000.00 | — |
| Gross margin | — | — | — | — |
| R&D | $38.23M | $230.63M | $355.89M | $238.06M |
| SG&A | $3.56M | $24.05M | $66.18M | $66.81M |
| Operating income | $-41.79M | $-254.68M | $-422.06M | $-316.26M |
| Operating margin | — | — | — | — |
| EBITDA | $-41.79M | $-64.77M | $-381.53M | $-247.80M |
| EBITDA margin | — | — | — | — |
| EBIT | $-41.79M | $-64.84M | $-381.64M | $-248.23M |
| Interest expense | — | — | — | — |
| Income tax | $-41794.00 | $-4.17M | $-52895.00 | — |
| Effective tax rate | 0.1% | 1.6% | 0.0% | 0.0% |
| Net income | $-41.84M | $-250.46M | $-381.64M | $-248.23M |
| Net income growth (YoY) | — | -498.6% | -52.4% | +35.0% |
| Profit margin | — | — | — | — |